NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

• Status: RECRUITING
• Trial end date: 2027-06-22

Summary

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

• Phase: PHASE1

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antiemetics; copper dotatate CU-64; gallium 68 PSMA-11; gallium Ga 68 dotatate; Gonadotropin-Releasing Hormone; Lutetium; Lutetium-177; Metoclopramide